Anti-Hypertensive Drugs - Germany

Germany

The revenue generated in the Anti-Hypertensive Drugs market in Germany is forecasted to reach €0.74bn in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 0.27%, leading to a market volume of €0.75bn by 2029.
When compared globally, United States is projected to generate the highest revenue of €11,400.00m in 2024.
Germany's pharmaceutical market is experiencing a surge in demand for anti-hypertensive drugs due to the country's aging population and increasing prevalence of hypertension.

Key regions: Japan, India, Italy, Brazil, South Korea

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The Anti-Hypertensive Drugs market in Germany has been experiencing steady growth in recent years.

Customer preferences: The demand for anti-hypertensive drugs in Germany has been on the rise due to the increasing prevalence of hypertension among the population. German consumers tend to prefer drugs that are effective and have minimal side effects. They also prefer drugs that are affordable and easily accessible.

Trends in the market: One of the major trends in the anti-hypertensive drugs market in Germany is the shift towards combination therapies. Combination therapies involve the use of two or more drugs to treat hypertension. This approach has been found to be more effective than monotherapy in some cases. Another trend is the increasing use of generic drugs. Generic drugs are cheaper than their branded counterparts and are becoming more widely accepted by patients and healthcare providers.

Local special circumstances: The German healthcare system is one of the most advanced in the world. The system is characterized by a high level of public funding and a strong emphasis on preventive care. The government plays a major role in regulating the pharmaceutical industry and ensuring that drugs are safe and effective. This has created a favorable environment for the development and marketing of anti-hypertensive drugs.

Underlying macroeconomic factors: The German economy is the largest in Europe and is driven by a strong manufacturing sector. The country has a highly educated workforce and a well-developed infrastructure. These factors have contributed to the growth of the pharmaceutical industry in Germany. The aging population is also a major factor driving the demand for anti-hypertensive drugs. As the population ages, the prevalence of hypertension is expected to increase, leading to higher demand for these drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.